Martin Pichler
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (13)
Purpose: Surveillance of clinical stage I (CSI) testicular germ cell tumors (GCT) is hampered by low sensitivity and specificity of current biomarkers for detecting relapses. This study evaluated if serum levels of microRNA371a-3p (M371 test) can: (i) Accurately detect relapses, (ii) detect relapses earlier than conventional technology, and (iii) if elevated postoperative M371 levels may predict relapse. Experimental Design: In a multicentric setting, 258 patients with testicular CSI GCT were prospectively followed by surveillance for a median time of 18 months with serial measurements of serum M371 levels, in addition to standard diagnostic techniques. Diagnostic characteristics of M371 for detecting relapses were calculated using ROC curve analysis. Results: Thirty-nine patients recurred (15.1%), all with elevated M371 levels; eight without relapse had elevations, too. The test revealed the following characteristics: area under the ROC curve of 0.993, sensitivity 100%, specificity 96.3%, positive predictive value 83%, negative predictive value 100%. Earlier relapse detection with the test was found in 28%, with non-significant median time gain to diagnosis. Postoperative M371 levels did not predict future relapse. Conclusions: The sensitivity and specificity of the M371 test for detecting relapses in CSI GCTs are much superior to those of conventional diagnostics. However, post-orchiectomy M371 levels are not predictive of relapse, and there is no significant earlier relapse detection with the test. In all, there is clear evidence for the utility of the M371 test for relapse detection suggesting it may soon be ready for implementation into routine follow-up schedules for patients with testicular GCT.
Year:
2024
Purpose: Surveillance of clinical stage I (CSI) testicular germ cell tumors (GCT) is hampered by low sensitivity and specificity of current biomarkers for detecting relapses. This study evaluated if serum levels of microRNA371a-3p (M371 test) can: (i) Accurately detect relapses, (ii) detect relapses earlier than conventional technology, and (iii) if elevated postoperative M371 levels may predict relapse. Experimental Design: In a multicentric setting, 258 patients with testicular CSI GCT were prospectively followed by surveillance for a median time of 18 months with serial measurements of serum M371 levels, in addition to standard diagnostic techniques. Diagnostic characteristics of M371 for detecting relapses were calculated using ROC curve analysis. Results: Thirty-nine patients recurred (15.1%), all with elevated M371 levels; eight without relapse had elevations, too. The test revealed the following characteristics: area under the ROC curve of 0.993, sensitivity 100%, specificity 96.3%, positive predictive value 83%, negative predictive value 100%. Earlier relapse detection with the test was found in 28%, with non-significant median time gain to diagnosis. Postoperative M371 levels did not predict future relapse. Conclusions: The sensitivity and specificity of the M371 test for detecting relapses in CSI GCTs are much superior to those of conventional diagnostics. However, post-orchiectomy M371 levels are not predictive of relapse, and there is no significant earlier relapse detection with the test. In all, there is clear evidence for the utility of the M371 test for relapse detection suggesting it may soon be ready for implementation into routine follow-up schedules for patients with testicular GCT.
Year:
2024
Year:
2023
Year:
2023
Year:
2023
MicroRNAs (miRNAs) are crucial post-transcriptional regulators of gene expression, and their deregulation contributes to many aspects of cancer development and progression. Thus, miRNAs provide insight into oncogenic mechanisms and represent promising targets for new therapeutic approaches. A type of cancer that is still in urgent need of improved treatment options is triple negative breast cancer (TNBC). Therefore, we aimed to characterize a novel miRNA with a potential role in TNBC. Based on a previous study, we selected miR-4646-5p, a miRNA with a still unknown function in breast cancer. We discovered that higher expression of miR-4646-5p in TNBC patients is associated with better survival. In vitro assays showed that miR-4646-5p overexpression reduces growth, proliferation, and migration of TNBC cell lines, whereas inhibition had the opposite effect. Furthermore, we found that miR-4646-5p inhibits the tube formation ability of endothelial cells, which may indicate anti-angiogenic properties. By whole transcriptome analysis, we not only observed that miR-4646-5p downregulates many oncogenic factors, like tumor-promoting cytokines and migration- and invasion-related genes, but were also able to identify a direct target, the GRAM domain-containing protein 1B (GRAMD1B). GRAMD1B is involved in cellular cholesterol transport and its knockdown phenocopied the growth-reducing effects of miR-4646-5p. We thus conclude that GRAMD1B may partly contribute to the diverse tumor-suppressive effects of miR-4646-5p in TNBC.
Year:
2023
Year:
2023
Year:
2023
Year:
2022
Year:
2022
Year:
2021
Year:
2021
Year:
2021
Collaborators (25)
Julia Heinzelbecker
Clinic director
Philipps-Universität Marburg
Josef Smolle
Professor
Medical University of Graz
Erika Richtig
Prof
Medical University of Graz
Ralf Küppers
Professor
Universität Duisburg-Essen
Luis A. Kluth
-
Laura Liesinger
TU Wien
Akos Heinemann
Professor
Medical University of Graz
Axel Heidenreich
-
Peter Törzsök
Paracelsus Medical University
Ruth Birner-Gruenberger
Full Professor
TU Wien
Joerg Lindenmann
Medical University of Graz
Gerald Hoefler
Professor for Pathology
Medical University of Graz
Cátia Pacífico
-
Klaus-Peter Dieckmann
Prof
Asklepios Klinik Altona
Jürgen Eberle
Charité - Universitätsmedizin Berlin
Freyja Maria Smolle-Juettner
Head of Division
Medical University of Graz
Alan Ramsay
King’s College London
Frédéric Santer
Principal Investigator
Medical University of Innsbruck
Jelena Krstic
Assistant Professor
Medical University of Graz
Josef Fritz
Medical University of Innsbruck
Alexander Winter
-
Gennadi Tulchiner
Medical University of Innsbruck
Renate Pichler
Medical University of Innsbruck
Wilfried Renner
Medical University of Graz
Beate Rinner
Head of Core Facility Alternative Biomodels and Preclinical Imaging
Medical University of Graz
Make your next move.
Prepare your application
Review drafts before you send them.